The reason why larger quantities of blood are routinely collected pertains not to the quantity used in the actual biochemical assay, but to the number of tests that may be carried out, and the greater ease of handling slightly larger quantities of sample than Theranos aims (aimed?) to handle. That is for their scientific model.
Their business model was based mostly on enabling blood to collected without the need for a qualified person (e.g. a phlebotomist or nurse). This they could do because the amount of blood collected, and the method of collection, circumvented existing legislation. However, if it turns out that this method of collection doesn't "scale" then it too is a wash.
Their saving grace might be if they can show that they can indeed perform assays on non-professionally collected blood to FDA-level standards. But that remains to be shown.
The following press release only mentions two other members (one of whom is the CEO). It also uses the future tense to say "Theranos’ Scientific and Medical Advisory Board will meet quarterly."
http://www.businesswire.com/news/home/20160407006056/en/Ther...
Is is appropriate to flag stories about Theranos? I doesn't seem appropriate to let them have an unfettered voice.